Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Dawson

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Nature Communications|June 7, 2016
Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapesBernard Pereira, Suet-Feung Chin, Oscar M Rueda, et al.
Cancer Discovery|December 7, 2018
A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast CancerSheau W Lok, James R Whittle, François Vaillant, et al.
The Oncologist|March 12, 2022
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design SimulationLorenzo Gerratana, Jean-Yves Pierga, James M Reuben, et al.
Nature Communications|May 11, 2016
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapesBernard Pereira, Suet-Feung Chin, Oscar M Rueda, et al.
Science (New York, N.Y.)|March 21, 2020
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammationOmer Gilan, Inmaculada Rioja, Kathy Knezevic, et al.
Nature Communications|March 5, 2021
Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doublingIsmael A Vergara, Christopher P Mintoff, Shahneen Sandhu, et al.
Nature Communications|June 22, 2019
Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemiaCharles C Bell, Katie A Fennell, Yih-Chih Chan, et al.
Nature Communications|May 20, 2025
Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primaryRichard J Rebello, Atara Posner, Ruining Dong, et al.
Plos Medicine|June 4, 2010
Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studiesFiona M Blows, Kristy E Driver, Marjanka K Schmidt, et al.
Critical Reviews in Oncology/Hematology|February 18, 2019
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paperMassimo Cristofanilli, Jean-Yves Pierga, James Reuben, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Nature Communications|June 7, 2016
Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapesBernard Pereira, Suet-Feung Chin, Oscar M Rueda, et al.
Cancer Discovery|December 7, 2018
A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast CancerSheau W Lok, James R Whittle, François Vaillant, et al.
The Oncologist|March 12, 2022
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design SimulationLorenzo Gerratana, Jean-Yves Pierga, James M Reuben, et al.
Nature Communications|May 11, 2016
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapesBernard Pereira, Suet-Feung Chin, Oscar M Rueda, et al.
Science (New York, N.Y.)|March 21, 2020
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammationOmer Gilan, Inmaculada Rioja, Kathy Knezevic, et al.
Nature Communications|March 5, 2021
Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doublingIsmael A Vergara, Christopher P Mintoff, Shahneen Sandhu, et al.
Nature Communications|June 22, 2019
Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemiaCharles C Bell, Katie A Fennell, Yih-Chih Chan, et al.
Nature Communications|May 20, 2025
Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primaryRichard J Rebello, Atara Posner, Ruining Dong, et al.
Plos Medicine|June 4, 2010
Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studiesFiona M Blows, Kristy E Driver, Marjanka K Schmidt, et al.
Critical Reviews in Oncology/Hematology|February 18, 2019
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paperMassimo Cristofanilli, Jean-Yves Pierga, James Reuben, et al.
Pageof 9